Navigation Links
Marinus Pharmaceuticals Raises $20 Million in Series B Financing
Date:4/10/2009

Company to Advance Ganaxolone Program for the Treatment of Epilepsy

BRANFORD, Conn., April 10 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., a developer of drugs to treat serious neurological and psychiatric disorders, today announced the close of a $20 million Series B financing. The funding comes on the heels of the Company's recent announcement of positive Phase 2a data for ganaxolone as an adjunctive therapy in adults with partial onset seizures. The Series B financing included participation from all of Marinus' existing investors, including Canaan Partners, Domain Associates, Sofinnova Ventures and Foundation Medical Partners.

"We've made tremendous strides since our Series A financing, with the completion of two Phase 2a clinical trials for ganaxolone in two separate indications, significant patent applications to protect our intellectual property, and advances on formulations which resulted in novel IP and a strong commercial candidate," said John Krayacich, president and CEO of Marinus Pharmaceuticals. "In light of this challenging environment, the continued support from our syndicate of premier life sciences investors validates our efforts, reinforces our accomplishments, and allows us to further advance this unique therapy which we hope will provide an additional alternative for people with epilepsy."

The funding will advance the Company's ganaxolone development program for use as a novel adjunctive agent for the treatment of refractory partial seizures and to explore proof of concept studies in psychiatric indications. Marinus Pharmaceuticals has raised a total of $50 million in private financing to date.

"The management team brings proven and distinctive expertise in developing CNS therapies," said Stephen Bloch, M.D., Partner at Canaan Partners and Chairman of Marinus Pharmaceuticals. "Marinus has made significant advances with this novel first in class neuroactive steroid as an
'/>"/>

SOURCE Marinus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
2. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
3. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
4. Gemin X Pharmaceuticals Selects and Deploys Clinical Force CTMS
5. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
6. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
7. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
8. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
9. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
10. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
11. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014  Xencor, Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune ... announced the appointment of Debra Zack , ... appointment of Lloyd Rowland , senior vice ... "Debra,s expertise in biologics clinical development ...
(Date:9/2/2014)... , Sept. 2, 2014  Spherix Incorporated (SPEX) -- an ... monetization of intellectual property, today announced that the United ... to the Company in the month of August that ... The issued patents are: ... U.S.RE45,081 issued August 19, 2014; and , U.S.RE45,095 ...
(Date:9/1/2014)... Albany, NewYork (PRWEB) September 01, 2014 ... Pharma, Biotech and Diagnostics report provides comprehensive understanding ... and agreements entered into by the worlds leading ... detailed understand and analysis of how and why ... flexibility of a prospective partner’s negotiated deals terms ...
(Date:8/30/2014)... 2014 The Global and China ... in-depth study on the current state of the ... , The report provides a basic overview of ... structure. Global market analysis and Chinese domestic market ... developments, trends and competitive landscape of the market. ...
Breaking Biology Technology:Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3
... Bioinformatics Application. Part of "Project GreenLight" Energy Efficiency Initiative. ... ... 17, 2008 -- Convey Computer Corporation today announced at SC08 ... Convey HC-1, to the University of California, San Diego as ...
... Physicists in the USA and at the London Centre for ... of electrons by more than 5,000 per cent, as reported ... a property called ,spin, and work like tiny magnets which ... The state of the spin can be used to store ...
... University of Central Florida researcher may have found a defense ... third of Europe,s population in the Middle Ages and which ... UCF Professor Henry Daniell and his team have developed a ... plague. Findings of his National Institutes of Health and USDA ...
Cached Biology Technology:Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference 2Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference 3Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference 4Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference 5UCF professor develops vaccine to protect against black plague bioterror attack 2UCF professor develops vaccine to protect against black plague bioterror attack 3
(Date:9/2/2014)... digital distribution of media will have lower carbon ... when file sizes are large. , That,s the ... Journal of Industrial Ecology that looked at ... as PlayStation3. Researchers found that Blu-ray Discs delivered ... than game files downloaded over broadband Internet. For ...
(Date:9/2/2014)... new study that could ultimately lead to many new ... Research Institute (TSRI) have adapted a chemical approach to ... that can treat a form of muscular dystrophy. , ... a disease-causing defect as a catalyst to synthesize a ... Disney.,"Because the treatment is synthesized only in diseased cells, ...
(Date:9/2/2014)... participation of the University of Granada has revealed new ... the Iberian Peninsula around the mid Holocene (around 6.000 ... from the Sahara increased. The data came from a ... in Sierra Nevada (Granada) , This study, published in ... the sedimentation of atmospheric dust from the Sahara, a ...
Breaking Biology News(10 mins):Scripps Florida scientists make diseased cells synthesize their own drug 2Scientists obtain new data on the weather 10,000 years ago from sediments of a lake in Sierra Nevada 2
... , Aug. 19, 2013 /PRNewswire-iReach/ -- Jade Holding Group, LLC dba ... and wellness centers, has just announced that Dr. Paul J. ... August. (Photo: http://photos.prnewswire.com/prnh/20130819/MN65951 ) Dr. ... in 1970 as an undergraduate at the University of Miami in ...
... microorganismshundreds to thousands of species of bacteria collectively called ... healthy existence. The gastrointestinal (GI) tractand the colon in ... of bacterial species. But how do these organisms persist ... flux due to foods and fluids moving through it? ...
... August 19, 2013 A study published today found ... accurate and precise method for quality control of next-generation sequencing ... data yield, thereby increasing efficiency and throughput while lowering cost. ... of Biotechniques . "While real-time PCR has ...
Cached Biology News:Dr. Paul J. Reilly, MD, FAAFP, is Named Strax Rejuvenation's Doctor of the Month for August 2Dr. Paul J. Reilly, MD, FAAFP, is Named Strax Rejuvenation's Doctor of the Month for August 3A home for the microbiome 2A home for the microbiome 3A home for the microbiome 4Droplet Digital™ PCR provides accurate quantification of next-generation sequencing libraries 2
... unique human proteins on a 1x3 ... a cross section of all cellular ... high-quality results. Additional control proteins and ... validity and reproducibility., ,UNIchip protein microarrays ...
... UNIchip AV-400 contains 400 unique ... nitrocellulose-coated glass slide. The proteins, all ... Ontology classification, are arrayed in quadruplicate ... and a specific chip layout guarantee ...
... The Sub-Plates are E.Coli glycerol stocks ... well contains 50 cDNA clones with approximately ... of the a master plate well, the ... 96-well PCR to identify the positive well(s). ...
... The TNT Coupled Reticulocyte Lysate ... eukaryotic in vitro translations: a single-tube, ... Systems greatly simplify the process and ... in vitro translation results. Standard rabbit ...
Biology Products: